Clinical Trials

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT07428018 2026-03-05

VIOLET

150 enrolled

Breast Neoplasms

NCT03130439 2026-02-20

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

27 enrolled 17 charts

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

189 enrolled

Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT07292207 2025-12-18

ARCHE

30 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT04305834 2025-09-24

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Breast Neoplasms

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

60 enrolled

Breast Neoplasms

NCT04523857 2025-04-04

ABBY

66 enrolled

Breast Neoplasms

NCT06259929 2025-02-18

Neo-AGILE

51 enrolled

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

29 enrolled

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

260 enrolled

Breast Neoplasms

NCT03703466 2024-04-02

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

72 enrolled 19 charts

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

60 enrolled

Breast Neoplasms

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT02308020 2020-12-19

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

BreastCNSDermatologicThoracic

162 enrolled 25 charts

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02441946 2020-06-17

neoMONARCH

224 enrolled 20 charts

Breast Neoplasms

NCT02102490 2020-01-21

MONARCH 1

132 enrolled 17 charts 1 FDA

Breast Neoplasms

NCT02831530 2018-03-29

ABC-POP

101 enrolled